2024年7月3日 · Apnimed envisions a new era for obstructive sleep apnea (OSA) and other sleep-related breathing diseases—where novel oral therapies simplify treatment and help more people get the oxygen and restorative sleep needed to thrive.

2024年7月3日 · Apnimed is a pharmaceutical company dedicated to breathing new life into the sleep-related breathing disease treatment landscape through innovation in oxygenation. Deep expertise fuels our team’s pursuit of solutions, giving us a unique scientific, clinical, and commercial edge.

Apnimed, Inc., a pharmaceutical company focused on discovery, development, and commercialization of first-in-class oral therapies that address the neuromuscular dysfunction of obstructive...

Apnimed, Inc., a pharmaceutical company focused on discovery, development, and commercialization of first-in-class oral therapies that address the neuromuscular dysfunction of obstructive...

2024年7月3日 · Our leadership team—which includes our Board of Directors and Scientific Advisory Board—is deeply committed to discovering, developing, and commercializing novel, first-in-class oral therapies that address the neuromuscular dysfunction of …

2023年11月1日 · Apnimed’s lead development program targets the neurologic control of upper airway muscles to maintain an open airway during sleep. Based in Cambridge, Mass., the company is developing a portfolio of novel pharmacologic therapies for sleep apnea and related disorders. Learn more at apnimed.com or follow us on X and LinkedIn.

Trademark applications and grants for Apnimed, Inc.. Apnimed, Inc. has 6 trademark applications. The latest application filed is for "CIRQO"

Apnimed is a clinical-stage company focused on advancing oral medicines to treat Obstructive Sleep Apnea (OSA) and related disorders. We asked 1,500 people with obstructive sleep apnea...

2024年10月9日 · Apnimed, Inc., today announced the results of its Sleep Health Inquiries on Needs and Emotions (SHINE) survey of 1,500 people living with obstructive sleep apnea (OSA).

CAMBRIDGE, Mass., October 31, 2023 – Apnimed, Inc., a clinical-stage pharmaceutical company focused on developing oral pharmacologic therapies for the treatment of obstructive sleep apnea (OSA) and other sleep disorders, announced a new joint venture with Shionogi & Co., Ltd., a leading global research-driven pharmaceutical company based in Japa...